merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>FDA approval and safety oversight of Zepbound vials compared to compounded drugs</answer>
<question_number>2</question_number>
<answer>It offers a cheaper, FDA-approved alternative through its own telehealth platform</answer>
<question_number>3</question_number>
<answer>lack of FDA approval and safety, quality, and effectiveness controls</answer>
<question_number>4</question_number>
<answer>to win back customers from compounded drug providers by undercutting prices</answer>
<question_number>5</question_number>
<answer>compounding pharmacies can legally produce tirzepatide while it's on the FDA shortage list</answer>
<question_number>6</question_number>
<answer>eliminating third-party supply chain entities to offer transparent pricing</answer>
<question_number>7</question_number>
<answer>older patients on Medicare may be drawn to the drug despite associated health risks</answer>
<question_number>8</question_number>
<answer>positions Zepbound vials as a safer, FDA-approved alternative</answer>
<question_number>9</question_number>
<answer>being listed as "in shortage" by the FDA</answer>
<question_number>10</question_number>
<answer>offering lower pricing to compete with compounded alternatives</answer>